rofecoxib and Rheumatoid Arthritis studies

Research Excerpts

Excerpt	Relevance	Reference
"In this multicentre, randomised, double blind, 12 week study, patients with rheumatoid arthritis were allocated to rofecoxib 50 mg once daily (n=219), naproxen 500 mg twice daily (n=220), or placebo (n=221)."	9.10	Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. ( Evans, J; Hawkey, CJ; Laine, L; Quan, H; Shingo, S; Simon, T, 2003)
" We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis."	9.09	Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000)
" This 8-week, double-masked, placebo-controlled trial was undertaken to assess the safety profile, tolerability, and effective dose range of once-daily rofecoxib, a COX-2-specific inhibitor, in the treatment of rheumatoid arthritis (RA)."	9.09	The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. ( Block, J; Bolognese, J; Dalgin, P; Ehrich, EW; Fleischmann, R; Schnitzer, TJ; Seidenberg, B; Truitt, K; Zeng, Q, 1999)
" Methotrexate is a disease-modifying agent with a narrow therapeutic index frequently prescribed for the management of rheumatoid arthritis."	9.09	Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. ( Agrawal, NG; Bachmann, KA; Ebel, DL; Gertz, BJ; Holmes, GB; Miller, JL; Porras, AG; Redfern, JS; Sack, MR; Schwartz, JI; Wong, PH, 2001)
"To examine the incidence of gastrointestinal (GI) events in patients with rheumatoid arthritis (RA) after the removal of rofecoxib from the market."	7.78	Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. ( Anis, AH; Colley, L; Esdaile, JM; Harvard, SS; Lacaille, D; Lynd, LD; Marra, CA; Schwenger, E, 2012)
"Compared with nonusers, after adjusting for age, sex, presence of RA, and history of heart disease and hypertension, patients using rofecoxib, but not celecoxib or NS NSAID, had an increased rate of edema (23."	7.72	Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004)
"Our analysis suggests that the competing risks of upper gastrointestinal toxicity and myocardial infarction shown in the VIGOR trial would project a longer life expectancy with naproxen than rofecoxib among patients with rheumatoid arthritis, except in those at low risk of myocardial infarction or at high risk of upper gastrointestinal toxicity."	7.72	Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2004)
" In the comparative trial, rofecoxib at a dosage of 50 mg/day demonstrated similar efficacy to naproxen at a dosage of 500 mg twice daily."	6.43	Rofecoxib for rheumatoid arthritis. ( Fidan, DD; Frankish, RR; Garner, SE; Judd, MG; Towheed, TE; Tugwell, P; Wells, G, 2005)
"Rofecoxib was associated with a greater risk for MI, but the exact significance and pathophysiology of this possible relationship is unclear."	6.41	Rofecoxib for the treatment of rheumatoid arthritis. ( Fidan, D; Frankish, R; Garner, S; Judd, M; Towheed, T; Tugwell, P; Wells, G, 2002)
"Rofecoxib was associated with a greater risk for MI, but the exact significance and pathophysiology of this possible relationship is unclear."	6.41	Rofecoxib for the treatment of rheumatoid arthritis. ( Fidan, D; Frankish, R; Garner, S; Judd, M; Towheed, T; Tugwell, P; Wells, G, 2002)
"Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin."	6.41	Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. ( Figgitt, DP; Matheson, AJ, 2001)
"Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, now being increasingly used in place of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs)."	5.33	Intracranial hypertension induced by rofecoxib. ( Jacob, S; Rajabally, YA, 2005)
"Rofecoxib have been shown to be associated with a reduced incidence of gastric erosions on endoscopy compared to standard NSAIDs in patients with arthritis."	5.32	[Rofecoxib: its efficacy in rheumatoid arthritis and acute pain]. ( Morović-Vergles, J, 2003)
"Celecoxib was dominated by diclofenac in average-risk patients."	5.32	The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003)
"Rofecoxib is a nonsteroidal anti-inflammatory drug that is reported to act by selectively inhibiting cyclooxygenase-2."	5.31	Aseptic meningitis associated with rofecoxib. ( Beitz, J; Bonnel, RA; Karwoski, CB; Villalba, ML, 2002)
"Eight thousand seventy-six rheumatoid arthritis patients aged >or=50 years (or >or=40 on corticosteroid therapy) were randomly assigned to rofecoxib 50 mg daily or naproxen 500 mg twice daily for a median of 9 months."	5.10	Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. ( Bombardier, C; Brett, C; Davis, B; Hawkey, CJ; Laine, L; Reicin, A; Shapiro, D, 2002)
"9% per year in rheumatoid arthritis patients taking the nonselective NSAID naproxen, accounting for nearly 40% of the serious GI events that developed in these patients."	5.10	Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. ( Bombardier, C; Burgos-Vargas, R; Connors, LG; Hawkey, CJ; Laine, L; Reicin, A; Schnitzer, TJ; Yu, Q, 2003)
"In this multicentre, randomised, double blind, 12 week study, patients with rheumatoid arthritis were allocated to rofecoxib 50 mg once daily (n=219), naproxen 500 mg twice daily (n=220), or placebo (n=221)."	5.10	Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. ( Evans, J; Hawkey, CJ; Laine, L; Quan, H; Shingo, S; Simon, T, 2003)
" This 8-week, double-masked, placebo-controlled trial was undertaken to assess the safety profile, tolerability, and effective dose range of once-daily rofecoxib, a COX-2-specific inhibitor, in the treatment of rheumatoid arthritis (RA)."	5.09	The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. ( Block, J; Bolognese, J; Dalgin, P; Ehrich, EW; Fleischmann, R; Schnitzer, TJ; Seidenberg, B; Truitt, K; Zeng, Q, 1999)
" Methotrexate is a disease-modifying agent with a narrow therapeutic index frequently prescribed for the management of rheumatoid arthritis."	5.09	Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. ( Agrawal, NG; Bachmann, KA; Ebel, DL; Gertz, BJ; Holmes, GB; Miller, JL; Porras, AG; Redfern, JS; Sack, MR; Schwartz, JI; Wong, PH, 2001)
" We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis."	5.09	Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. ( Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D, 2000)
"We know from adult randomised controlled trials that some NSAIDs, such as ibuprofen, naproxen, and aspirin, can be effective in certain chronic pain conditions."	4.95	Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. ( Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM, 2017)
"Although the published literature is limited, the data indicate that rofecoxib is an effective analgesic agent for the painful conditions in which it has been studied."	4.81	Rofecoxib: clinical pharmacology and clinical experience. ( Weaver, AL, 2001)
"To examine the incidence of gastrointestinal (GI) events in patients with rheumatoid arthritis (RA) after the removal of rofecoxib from the market."	3.78	Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. ( Anis, AH; Colley, L; Esdaile, JM; Harvard, SS; Lacaille, D; Lynd, LD; Marra, CA; Schwenger, E, 2012)
"During the review process of the Vioxx Gastrointestinal Outcomes Research study, it was suggested that rofecoxib might have little benefit, with regard to GI toxicity, for patients with rheumatoid arthritis not treated with corticosteroids."	3.77	Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. ( Chan, FK; Graham, DY; Jewell, NP, 2011)
" Ischemic stroke was predicted by hypertension, myocardial infarction, low-dose aspirin, comorbidity score, Health Assessment Questionnaire score, and presence of total joint replacement, but not by diabetes, smoking, exercise, or body mass index."	3.74	Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. ( Hallenbeck, JM; Michaud, K; Nadareishvili, Z; Wolfe, F, 2008)
" We report two cases of acute psychotic syndromes with visual (Case 1 + 2) and auditory (Case 1) hallucinations under rofecoxib, a cyclooxygenase-2-inhibitor."	3.74	[Rofecoxib-induced psychosis]. ( Connemann, BJ; Kassubek, J; Sabolek, M; Sperfeld, AD; Unrath, A, 2007)
" This study evaluated average daily doses and costs of rofecoxib and celecoxib and concomitant use of gastroprotective agents (GPAs) in elderly patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in Quebec, prior to the rofecoxib withdrawal."	3.73	Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? ( Chabot, I; Hunsche, E; Rahme, E; Toubouti, Y, 2006)
"This study assessed prescribing patterns for rofecoxib and celecoxib in the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as differences in prescribing patterns across physician specialties."	3.72	An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. ( Kong, SX; Mavros, P; Mitchell, JH; Pellissier, JM; Schnitzer, TJ; Straus, WL; Watson, DJ, 2003)
"A total of 3639 patients with rheumatoid arthritis (RA), osteoarthritis, and fibromyalgia starting therapy of celecoxib, rofecoxib, naproxen, or ibuprofen were surveyed at 6-month intervals for up to 2."	3.72	Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. ( Burke, TA; Michaud, K; Wolfe, F; Zhao, SZ, 2004)
"A 73-year-old woman was prescribed rofecoxib 25 mg/day for rheumatoid arthritis in addition to other medications on which the patient had been stabilized."	3.72	Lichenoid drug eruption probably associated with rofecoxib. ( Abu-Shraie, NA; Alfadley, AA, 2004)
"Compared with nonusers, after adjusting for age, sex, presence of RA, and history of heart disease and hypertension, patients using rofecoxib, but not celecoxib or NS NSAID, had an increased rate of edema (23."	3.72	Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004)
"Our analysis suggests that the competing risks of upper gastrointestinal toxicity and myocardial infarction shown in the VIGOR trial would project a longer life expectancy with naproxen than rofecoxib among patients with rheumatoid arthritis, except in those at low risk of myocardial infarction or at high risk of upper gastrointestinal toxicity."	3.72	Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. ( Choi, HK; Kuntz, KM; Seeger, JD, 2004)
"A population of 6637 patients with rheumatoid arthritis (RA) and osteoarthritis (OA) from the practices of 433 US rheumatologists completed 2 sets of detailed questionnaires concerning (1) the last 6 months in 1998 and (2) the first 6 months of 1999, generally prior to and after the release of celecoxib and rofecoxib."	3.71	Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr ( Arguelles, LM; Burke, TA; Flowers, N; Pettitt, D; Wolfe, F, 2002)
" In the comparative trial, rofecoxib at a dosage of 50 mg/day demonstrated similar efficacy to naproxen at a dosage of 500 mg twice daily."	2.43	Rofecoxib for rheumatoid arthritis. ( Fidan, DD; Frankish, RR; Garner, SE; Judd, MG; Towheed, TE; Tugwell, P; Wells, G, 2005)
" The initial oral dosage of rofecoxib is 12."	2.41	[Pharma-clinics. The drug of the month. Rofecoxib (Vioxx)]. ( Scheen, AJ, 2000)
" Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone)."	2.41	Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. ( Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR, 2001)
" However, NSAIDs cause significant adverse upper gastrointestinal effects, including increased mortality from serious ulcer complications."	2.41	Selective inhibitors of COX-2--are they safe for the stomach? ( Giercksky, KE; Haglund, U; Rask-Madsen, J, 2000)
"Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin."	2.41	Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. ( Figgitt, DP; Matheson, AJ, 2001)
"Celecoxib and rofecoxib have been used in Norway since 2000."	2.41	[A critical evaluation of side effect data on COX-2 inhibitors]. ( Pomp, E, 2002)
"Rofecoxib was associated with a greater risk for MI, but the exact significance and pathophysiology of this possible relationship is unclear."	2.41	Rofecoxib for the treatment of rheumatoid arthritis. ( Fidan, D; Frankish, R; Garner, S; Judd, M; Towheed, T; Tugwell, P; Wells, G, 2002)
"Rofecoxib was associated with a greater risk for MI, but the exact significance and pathophysiology of this possible relationship is unclear."	2.41	Rofecoxib for the treatment of rheumatoid arthritis. ( Fidan, D; Frankish, R; Garner, S; Judd, M; Towheed, T; Tugwell, P; Wells, G, 2002)
"Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, now being increasingly used in place of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs)."	1.33	Intracranial hypertension induced by rofecoxib. ( Jacob, S; Rajabally, YA, 2005)
"Rofecoxib users were at a significantly increased relative risk of new onset hypertension compared with patients taking celecoxib (odds ratio [OR] 1."	1.32	Relationship between COX-2 specific inhibitors and hypertension. ( Avorn, J; Levin, R; Schneeweiss, S; Solomon, DH, 2004)
"Rofecoxib have been shown to be associated with a reduced incidence of gastric erosions on endoscopy compared to standard NSAIDs in patients with arthritis."	1.32	[Rofecoxib: its efficacy in rheumatoid arthritis and acute pain]. ( Morović-Vergles, J, 2003)
"Celecoxib was dominated by diclofenac in average-risk patients."	1.32	The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003)
"Rofecoxib is a nonsteroidal anti-inflammatory drug that is reported to act by selectively inhibiting cyclooxygenase-2."	1.31	Aseptic meningitis associated with rofecoxib. ( Beitz, J; Bonnel, RA; Karwoski, CB; Villalba, ML, 2002)
"Electrolyte disorders and acute renal failure are observed more frequently in patients with risk factors."	1.31	[Renal tolerance of selective inhibitors of cyclooxygenase type 2]. ( Deray, G, 2001)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (2.75)	18.2507
2000's	103 (94.50)	29.6817
2010's	3 (2.75)	24.3611
2020's	0 (0.00)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645]	Phase 2	60 participants (Actual)	Interventional	2006-10-31	Completed
Pre-Emptive Analgesic Effects of a Selective COX-2 Inhibitor (Rofecoxib) in the Oral Surgery Model[NCT00026819]	Phase 2	150 participants	Interventional	2001-11-30	Completed
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614]	Phase 2	58 participants (Actual)	Interventional	2003-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. The Cochrane database of systematic reviews, 2017, 08-02, Volume: 8 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Asp	2017
Rofecoxib for the treatment of rheumatoid arthritis. The Cochrane database of systematic reviews, 2002, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Lactones; Naproxen; Randomiz	2002
Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective. The American journal of managed care, 2002, Volume: 8, Issue:17 Suppl Topics: Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibito	2002
[The future of peptic ulcer disease without Helicobacter]. Praxis, 2003, Mar-19, Volume: 92, Issue:12 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin	2003
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Annals of internal medicine, 2003, May-20, Volume: 138, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib;	2003
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Expert opinion on drug safety, 2002, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Ce	2002
[Clinical pharmacology of the selective COX-2 inhibitors]. Der Orthopade, 2003, Volume: 32, Issue:12 Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis	2003
[Is there a future for COX-2 inhibitors?]. Harefuah, 2004, Volume: 143, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 I	2004
Rofecoxib for rheumatoid arthritis. The Cochrane database of systematic reviews, 2005, Jan-25, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug Appr	2005
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP. Clinical laboratory, 2005, Volume: 51, Issue:1-2 Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; Cardio	2005
Life after Vioxx: the clinical implications. Hospital medicine (London, England : 1998), 2005, Volume: 66, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Clinical Tr	2005
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. Current topics in medicinal chemistry, 2005, Volume: 5, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cy	2005
Clinical inquiries. Do COX-2 inhibitors worsen renal function? The Journal of family practice, 2007, Volume: 56, Issue:11 Topics: Arthritis, Rheumatoid; Celecoxib; Contraindications; Cyclooxygenase 2 Inhibitors; Humans; Kidney; La	2007
When to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations. Postgraduate medicine, 1999, Oct-01, Volume: 106, Issue:4 Topics: Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enz	1999
Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs. Geriatrics, 2000, Volume: 55, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthri	2000
[New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results]. Lakartidningen, 2000, Jun-14, Volume: 97, Issue:24 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trial	2000
[Pharma-clinics. The drug of the month. Rofecoxib (Vioxx)]. Revue medicale de Liege, 2000, Volume: 55, Issue:7 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biologi	2000
Selective inhibitors of COX-2--are they safe for the stomach? Scandinavian journal of gastroenterology, 2000, Volume: 35, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox	2000
Efficacy of cyclooxygenase-2-specific inhibitors. The American journal of medicine, 2001, Feb-19, Volume: 110 Suppl 3A Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyge	2001
COX-2 inhibitors in rheumatoid arthritis. Current rheumatology reports, 2001, Volume: 3, Issue:1 Topics: Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Digestive Sys	2001
Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs, 2001, Volume: 61, Issue:6 Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tri	2001
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis. Hand clinics, 2001, Volume: 17, Issue:2 Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumat	2001
COX-2 inhibition and thrombotic tendency: a need for surveillance. The Medical journal of Australia, 2001, Aug-20, Volume: 175, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I	2001
Rofecoxib: clinical pharmacology and clinical experience. Clinical therapeutics, 2001, Volume: 23, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Lactones; Osteoarthritis; Pa	2001
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation, 2001, Nov-06, Volume: 104, Issue:19 Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu	2001
[A critical evaluation of side effect data on COX-2 inhibitors]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2002, Feb-20, Volume: 122, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors	2002
[New nonsteroidal antiinflammatory drugs in rheumatoid arthritis]. Annales de medecine interne, 2002, Volume: 153, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Gastric Mucosa; Humans; L	2002
Rofecoxib for the treatment of rheumatoid arthritis. The Cochrane database of systematic reviews, 2002, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Lactones; Naproxen; Randomiz	2002
An update on specific COX-2 inhibitors: the COXIBs. Bulletin on the rheumatic diseases, 2001, Volume: 50, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox	2001

Article	Year
Anti-hyperalgesic effects of nimesulide: studies in rats and humans. International journal of clinical practice. Supplement, 2002, Issue:128 Topics: Aged; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid;	2002
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology, 2002, Volume: 123, Issue:4 Topics: Adrenal Cortex Hormones; Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Art	2002
A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis. Scandinavian journal of rheumatology, 2002, Volume: 31, Issue:4 Topics: Adult; Aged; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In	2002
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology, 2003, Volume: 124, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygen	2003
Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut, 2003, Volume: 52, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cycl	2003
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Jul-01, Volume: 61, Issue:13 Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxyge	2004
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clinical therapeutics, 1999, Volume: 21, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Double-Blind Metho	1999
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?]. Presse medicale (Paris, France : 1983), 2000, Mar-11, Volume: 29, Issue:9 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi	2000
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. The New England journal of medicine, 2000, 11-23, Volume: 343, Issue:21 Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors	2000
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. The New England journal of medicine, 2000, 11-23, Volume: 343, Issue:21 Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors	2000
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. The New England journal of medicine, 2000, 11-23, Volume: 343, Issue:21 Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors	2000
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. The New England journal of medicine, 2000, 11-23, Volume: 343, Issue:21 Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors	2000
[The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%]. Zeitschrift fur Gastroenterologie, 2001, Volume: 39, Issue:5 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Endoscopy, Gastrointestinal;	2001
Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. Journal of clinical pharmacology, 2001, Volume: 41, Issue:10 Topics: Adult; Aged; Analysis of Variance; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Co	2001

Article	Year
4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1) Journal of medicinal chemistry, 2002, Mar-28, Volume: 45, Issue:7 Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzenesulfonates; Cyclooxygenase 1; Cyclooxygenase	2002
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis and rheumatism, 2008, Aug-15, Volume: 59, Issue:8 Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An	2008
Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. The American journal of the medical sciences, 2011, Volume: 342, Issue:5 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2	2011
Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. The Journal of rheumatology, 2012, Volume: 39, Issue:5 Topics: Aged; Arthritis, Rheumatoid; British Columbia; Cohort Studies; Female; Gastrointestinal Diseases; Hu	2012
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, Jun-25, Volume: 166, Issue:13 Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Myocardi	2002
Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs. BMJ (Clinical research ed.), 2002, Jul-20, Volume: 325, Issue:7356 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic;	2002
[No chance for pain. Rofecoxib eases not only tooth extraction]. MMW Fortschritte der Medizin, 2002, Jun-27, Volume: 144, Issue:26 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; La	2002
Central retinal vein occlusion in a patient with rheumatoid arthritis taking rofecoxib. Lancet (London, England), 2002, Oct-05, Volume: 360, Issue:9339 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Causalit	2002
[Already the drug of choices in the USA. Coxibe in joint pain]. MMW Fortschritte der Medizin, 2002, Aug-08, Volume: 144, Issue:31-32 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug Appr	2002
[Financial interests characterize published reports on coxiber. Whom can we rely on?]. Lakartidningen, 2002, Oct-03, Volume: 99, Issue:40 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Cel	2002
COX-2 inhibitors: new drugs for the management of pain and inflammation. Dentistry today, 2001, Volume: 20, Issue:2 Topics: Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid	2001
[No loss of effectiveness with rofecoxib. Long-term control of rheumatoid pain]. MMW Fortschritte der Medizin, 2002, Nov-14, Volume: 144, Issue:46 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxyge	2002
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. Clinical therapeutics, 2003, Volume: 25, Issue:1 Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D	2003
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart]. MMW Fortschritte der Medizin, 2003, Mar-13, Volume: 145, Issue:11 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu	2003
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis. Annals of internal medicine, 2003, May-20, Volume: 138, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben	2003
The role of COX-2 in angiogenesis and rheumatoid arthritis. Experimental and molecular pathology, 2003, Volume: 74, Issue:3 Topics: Arthritis, Rheumatoid; Cells, Cultured; Chemotaxis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C	2003
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis and rheumatism, 2003, Jun-15, Volume: 49, Issue:3 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Canada; Cel	2003
Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford, England), 2003, Volume: 42, Issue:11 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Chi-	2003
[Selective COX 2 inhibitor rofecoxib. To "defy" the pain]. MMW Fortschritte der Medizin, 2003, Aug-07, Volume: 145, Issue:31-32 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors	2003
Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis and rheumatism, 2003, Volume: 48, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cells, Cultured; Colforsin; Cyclic A	2003
Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study. Arthritis and rheumatism, 2003, Volume: 48, Issue:11 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Clinical Trials as Topic; Computer Simulatio	2003
An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clinical therapeutics, 2003, Volume: 25, Issue:12 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi	2003
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. The Journal of rheumatology, 2004, Volume: 31, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Community Health Services	2004
Spanish drug editor wins case brought by Merck, Sharp Dohme. BMJ (Clinical research ed.), 2004, Feb-07, Volume: 328, Issue:7435 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Industry; Lactones; Liability,	2004
Lichenoid drug eruption probably associated with rofecoxib. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:5 Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug Eruptions; Female; Humans; Lactones; Su	2004
Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. The American journal of medicine, 2004, May-01, Volume: 116, Issue:9 Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Decision Support Techniques; Female; Gastroi	2004
[Rofecoxib: its efficacy in rheumatoid arthritis and acute pain]. Reumatizam, 2003, Volume: 50, Issue:2 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibi	2003
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiology and drug safety, 2004, Volume: 13, Issue:5 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inh	2004
Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. The Journal of rheumatology, 2004, Volume: 31, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecox	2004
[Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine]. MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Clinical Trials a	2004
Relationship between COX-2 specific inhibitors and hypertension. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 44, Issue:2 Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Hum	2004
Chlamydial infection preceding the development of rheumatoid arthritis: a brief report. Clinical rheumatology, 2004, Volume: 23, Issue:5 Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chlamy	2004
Failing the public health--rofecoxib, Merck, and the FDA. The New England journal of medicine, 2004, Oct-21, Volume: 351, Issue:17 Topics: Adverse Drug Reaction Reporting Systems; Advertising; Arthritis, Rheumatoid; Clinical Trials as Topi	2004
[Prescribing patterns of rofecoxib in the primary care setting: results of a French survey]. La Revue de medecine interne, 2004, Volume: 25, Issue:10 Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Arthritis; Arth	2004
UK patients seek compensation after taking rofecoxib. BMJ (Clinical research ed.), 2004, Dec-04, Volume: 329, Issue:7478 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Compensation and Redress; Humans; La	2004
Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics? Delaware medical journal, 2002, Volume: 74, Issue:12 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug Interactions; Ep	2002
The sad story of Vioxx, and what we should learn from it. Cleveland Clinic journal of medicine, 2004, Volume: 71, Issue:12 Topics: Arthritis, Rheumatoid; Drug Approval; Drug Industry; Humans; Lactones; Myocardial Infarction; Produc	2004
Intracranial hypertension induced by rofecoxib. Headache, 2005, Volume: 45, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Hum	2005
Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib). European journal of epidemiology, 2005, Volume: 20, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug and	2005
The Vioxx fallout. Minnesota medicine, 2005, Volume: 88, Issue:3 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumat	2005
[The medical reason for the prescription of COX-2 selective cyclo oxygenase inhibitor rofecoxib for the treatment of rheumatoid arthritis. A post-marketing surveillance study from Austria]. Wiener medizinische Wochenschrift (1946), 2005, Volume: 155, Issue:9-10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheu	2005
Simplified search strategies were effective in identifying clinical trials of pharmaceuticals and physical modalities. Journal of clinical epidemiology, 2005, Volume: 58, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Back Pain; Clinical Trials as Topic;	2005
Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? Arthritis and rheumatism, 2006, Feb-15, Volume: 55, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Costs and Cost Analysi	2006
Expression of concern reaffirmed. The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Lactones; Myocard	2006
Response to expression of concern regarding VIGOR study. The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Data Interpretation, Statistical; Gastrointestinal D	2006
Response to expression of concern regarding VIGOR study. The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11 Topics: Arthritis, Rheumatoid; Data Interpretation, Statistical; Gastrointestinal Diseases; Humans; Lactones	2006
Tumour necrosis factor-alpha blockers: potential limitations in the management of advanced endometriosis? A case report. Human reproduction (Oxford, England), 2006, Volume: 21, Issue:9 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 I	2006
[Rofecoxib-induced psychosis]. Psychiatrische Praxis, 2007, Volume: 34, Issue:4 Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Female; Follow-Up Studies; Hallucinations; H	2007
Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cohort Stud	2008
Rofecoxib associated with diaphragm disease. Canadian journal of surgery. Journal canadien de chirurgie, 2007, Volume: 50, Issue:6 Topics: Arthritis, Rheumatoid; Constriction, Pathologic; Cyclooxygenase 2 Inhibitors; Female; Humans; Intest	2007
Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma. Nature clinical practice. Rheumatology, 2008, Volume: 4, Issue:4 Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit	2008
Effect of inflammation on kidney function and pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib and meloxicam. Journal of applied toxicology : JAT, 2008, Volume: 28, Issue:7 Topics: Administration, Oral; Animals; Area Under Curve; Arthritis, Experimental; Arthritis, Rheumatoid; Cyc	2008
COX-2 inhibitors. Magic bullets or merely mortal? Harvard health letter, 2000, Volume: 25, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox	2000
[Specific COX-2 inhibitors. Also effective in arthritis?]. MMW Fortschritte der Medizin, 2000, Jan-20, Volume: 142, Issue:3 Topics: Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Hum	2000
COX-2 inhibitors. The Medical journal of Australia, 2000, Oct-16, Volume: 173, Issue:8 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenas	2000
[Rheumatism therapy, from the economic viewpoint. COX-2 inhibitor as cost saving drug]. MMW Fortschritte der Medizin, 2000, Nov-02, Volume: 142, Issue:44 Topics: Arthritis, Rheumatoid; Celecoxib; Cost Savings; Cyclooxygenase Inhibitors; Drug Costs; Germany; Lact	2000
[Therapy with rofecoxib. Decreasing risk by controlled COX-2 inhibitor administration]. MMW Fortschritte der Medizin, 2000, Nov-30, Volume: 142, Issue:48 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Enz	2000
[Stomach-saving "Coxibs". No reason for therapeutic risks]. MMW Fortschritte der Medizin, 2001, Jan-18, Volume: 143, Issue:3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Humans; Lactones; Peptic Ulc	2001
Is rofecoxib safer than naproxen? The Journal of family practice, 2001, Volume: 50, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Do	2001
Selective COX-2 inhibitors. The American journal of nursing, 2001, Volume: 101, Issue:4 Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib;	2001
[Results of the VIGOR study. Rofecoxib halves the complication rate]. MMW Fortschritte der Medizin, 2001, Jun-07, Volume: 143, Issue:23 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relationship, Dr	2001
[Selective COX-2 inhibitor. Stomach protection--but not always]. MMW Fortschritte der Medizin, 2001, Jun-21, Volume: 143, Issue:25 Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycl	2001
[Elderly patient with rheumatoid arthritis. Minimizing the peptic ulcer hemorrhage risk]. MMW Fortschritte der Medizin, 2001, Aug-09, Volume: 143, Issue:31-32 Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cycl	2001
[Renal tolerance of selective inhibitors of cyclooxygenase type 2]. Presse medicale (Paris, France : 1983), 2001, Oct-20, Volume: 30, Issue:30 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroida	2001
[Cox-2 inhibitors in the focus. Rofecoxib as effective as the "classics"]. MMW Fortschritte der Medizin, 2001, Nov-15, Volume: 143, Issue:46 Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal	2001
[Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine]. Zeitschrift fur Rheumatologie, 2001, Volume: 60, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2;	2001
Aseptic meningitis associated with rofecoxib. Archives of internal medicine, 2002, Mar-25, Volume: 162, Issue:6 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carpal Tunn	2002
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr The Journal of rheumatology, 2002, Volume: 29, Issue:5 Topics: Aged; Arthritis, Rheumatoid; Bias; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2;	2002
Selective COX-2 inhibition. Bulletin on the rheumatic diseases, 1999, Volume: 48, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors	1999

rofecoxib and Rheumatoid Arthritis

Research Excerpts

Research

Studies (109)

Authors

Clinical Trials (3)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Hashimoto, H	1
Imamura, K	1
Haruta, J	1
Wakitani, K	1
Eccleston, C	1
Cooper, TE	1
Fisher, E	1
Anderson, B	1
Wilkinson, NM	1
Nadareishvili, Z	1
Michaud, K	2
Hallenbeck, JM	1
Wolfe, F	4
Graham, DY	1
Jewell, NP	1
Chan, FK	1
Marra, CA	1
Lynd, LD	1
Colley, L	1
Harvard, SS	1
Lacaille, D	1
Schwenger, E	1
Anis, AH	1
Esdaile, JM	1
Wooltorton, E	1
Budenholzer, BR	1
Garner, S	2
Fidan, D	2
Frankish, R	2
Judd, M	2
Towheed, T	2
Wells, G	3
Tugwell, P	3
Bianchi, M	1
Broggini, M	1
Laine, L	5
Bombardier, C	5
Hawkey, CJ	6
Davis, B	3
Shapiro, D	4
Brett, C	1
Reicin, A	5
Geusens, PP	1
Truitt, K	2
Sfikakis, P	1
Zhao, PL	1
DeTora, L	1
Shingo, S	2
Lau, CS	1
Kalla, A	1
Tate, G	1
Meyer, Ch	1
Gähler, R	1
Håkansson, J	1
Hochberg, MC	4
Hutchins, V	1
Hutchins, B	1
Einecke, D	2
Connors, LG	1
Burgos-Vargas, R	3
Schnitzer, TJ	5
Yu, Q	1
Harley, C	1
Wagner, S	1
Lehmann, FS	1
Gyr, N	1
Simon, T	1
Quan, H	1
Evans, J	1
Spiegel, BM	1
Targownik, L	1
Dulai, GS	1
Gralnek, IM	1
Woods, JM	1
Mogollon, A	1
Amin, MA	1
Martinez, RJ	1
Koch, AE	1
Maetzel, A	1
Krahn, M	1
Naglie, G	1
Layton, D	1
Heeley, E	1
Hughes, K	1
Shakir, SA	1
Chiolero, A	1
Maillard, MP	1
Burnier, M	1
Kojima, F	1
Naraba, H	1
Sasaki, Y	1
Beppu, M	1
Aoki, H	1
Kawai, S	1
Anderson, JJ	1
Bolognese, JA	1
Felson, DT	1
Burian, M	1
Geisslinger, G	1
Kong, SX	1
Mitchell, JH	1
Mavros, P	1
Watson, DJ	1
Pellissier, JM	1
Straus, WL	1
Burke, TA	3
Zhao, SZ	2
Gibson, L	1
Abu-Shraie, NA	1
Alfadley, AA	1
Choi, HK	1
Seeger, JD	1
Kuntz, KM	1
Morović-Vergles, J	1
Wentworth, C	1
Makuch, RW	1
Zhao, S	1
Pettitt, D	2
Solomon, DH	1
Schneeweiss, S	1
Levin, R	1
Avorn, J	1
Tran, F	1
Boggie, DT	1
Delattre, ML	1
Schaefer, MG	1
Morreale, AP	1
Plowman, BK	1
Jolly, M	1
Curran, JJ	1
Topol, EJ	2
Bannwarth, B	1
Logeart, I	1
Vergult, G	1
Dyer, C	1
Vincent, S	1
Slease, RB	1
Rocca, PV	1
Yodfat, Y	1
Karha, J	1
Jacob, S	1
Rajabally, YA	1
Garner, SE	1
Fidan, DD	1
Frankish, RR	1
Judd, MG	1
Towheed, TE	1
Giannitsis, E	1
Carné, X	1
Cruz, N	1
Palmer, K	1
Fortun, PJ	1
Lüth, P	1
Herold, M	1
Mur, E	1
Day, D	1
Furlan, A	1
Irvin, E	1
Rahme, E	1
Hunsche, E	1
Toubouti, Y	1
Chabot, I	1
Curfman, GD	1
Morrissey, S	1
Drazen, JM	1
Day, R	2
Ferraz, MB	2
Kvien, TK	2
Weaver, A	1
Shakiba, K	1
Falcone, T	1
Sabolek, M	1
Unrath, A	1
Sperfeld, AD	1
Connemann, BJ	1
Kassubek, J	1
Sukel, MP	1
van der Linden, MW	1
Chen, C	1
Erkens, JA	1
Herings, RM	1
Wall, R	1
Strickland, C	1
Jamieson, B	1
Lo, V	1
Lapner, MA	1
Stephen, WJ	1
Mielke, F	1
Schweigert, M	1
Harirforoosh, S	1
Jamali, F	1
Rehman, Q	1
Sack, KE	1
Fleischmann, R	1
Dalgin, P	1
Block, J	1
Zeng, Q	1
Bolognese, J	1
Seidenberg, B	1
Ehrich, EW	1
Infante, R	1
Lahita, RG	1
Blondon, H	1
Oliw, E	1
Wollheim, FA	1
Scheen, AJ	1
Brooks, PM	1
Day, RO	1
Giercksky, KE	1
Haglund, U	1
Rask-Madsen, J	1
Cannon, GW	1
Breedveld, FC	1
Sundy, JS	1
Adelman, A	1
Pasero, C	1
McCaffery, M	1
Matheson, AJ	1
Figgitt, DP	1
Kellner, H	1
Wildy, KS	1
Wasko, MC	1
Schwartz, JI	1
Agrawal, NG	1
Wong, PH	1
Bachmann, KA	1
Porras, AG	1
Miller, JL	1
Ebel, DL	1
Sack, MR	1
Holmes, GB	1
Redfern, JS	1
Gertz, BJ	2
Cleland, LG	1
James, MJ	1
Stamp, LK	1
Penglis, PS	1
Weaver, AL	1
Konstam, MA	1
Weir, MR	1
Sperling, RS	1
Barr, E	1
Deray, G	1
Krüger, K	1
Bonnel, RA	1
Villalba, ML	1
Karwoski, CB	1
Beitz, J	1
Pomp, E	1
Berenbaum, F	1
Flowers, N	1
Arguelles, LM	1
Silas, S	1
Clegg, DO	1
Gupta, S	1
Crofford, LJ	1